Under homeostatic conditions, Keap1 constitutively mediates the proteasomal 
Introduction
Keap1 is a cytoplasmic protein that aids in the constitutive degradation of Nrf2 (1) .
Oxidation of key cysteines on Keap1 in response to changes in the cellular environment allows for disruption of Nrf2 ubiquitination and Nrf2 accumulation due to decreased protein turnover (2) . Nrf2 subsequently translocates to the nucleus, where it forms a heterodimer with a small Maf protein to transcriptionally regulate inducible expression of cytoprotective genes (3) via cis-acting antioxidant/electrophile responsive elements (ARE/EpRE) (4) . As Nrf2 regulates a multitude of detoxification and antioxidant enzymes, Nrf2-deficient mice are susceptible to a variety of electrophilic or oxidative insults (5) (6) (7) (8) . When murine Keap1 is disrupted, constitutive Nrf2 activation manifests as in vivo juvenile lethality due to the Nrf2-mediated formation of hyperkeratotic obstructive lesions in the esophagus (9) . Importantly, simultaneous deletion of the Nrf2 or small Maf in tandem with Keap1 (9, 10) can prevent premature lethality in double-null mice, indicating that Keap1 is essential in preventing hyperkeratosis caused by excessive activity of the Nrf2-small Maf heterodimer complex. These and other studies have revealed that Keap1 acts as a sensor for electrophilic and oxidative stresses to maintain proper Nrf2 activity. However, Keap1 function can be abolished or diminished to generate a cytoprotective response when conditions dictate.
Available lines of evidence suggest that integrity of the Keap1 tertiary structure is crucial in mediating the ubiquitination of Nrf2. Keap1 consists of three major domains, a Broad-complex, Tramtrack and Bric-a-Brac (BTB) domain, an intervening region (IVR) and a double glycine repeat plus C-terminal (DC) domain. Each of these domains has a defined function and plays an integral role in Keap1 activity. The BTB domain is critical for the homodimerization of Keap1 (11) , whereas the IVR domain has an important role in binding to Cul3 and supporting the E3 ligase complex necessary for Nrf2 ubiquitination (1) . This region also houses critical electrophile-responsive cysteines. Covalent modifications of these cysteines cause changes in Keap1 that interfere with Nrf2 ubiquitination/degradation and allow for increased Nrf2 levels, in essence enabling the cytoprotective response (12) . Two critical cysteines in the IVR are C273 and C288, both of which are known to be responsive to oxidative stress, and mutations cause constitutive Nrf2 activation in vivo (13) . Finally the DC domain is essential for interaction with Neh2 domain of Nrf2 (14) . The Neh2 domain of Nrf2 contains the DLG and ETGE motifs that independently interact with the pocket on the bottom of Keap1 DC domain (15) .
Recent genotyping of human cancers have revealed several somatic mutations that cause constitutive NRF2 activation (16) (17) (18) (19) . Although the epidemiological data on tumor samples has been limited thus far, it was noted that the mutation rate for KEAP1 and NRF2 is estimated to be 25% in lung tumors when both NRF2 and KEAP1 mutations are tallied together (20) . Empirical evidence from these studies has suggested that KEAP1 mutations primarily cluster in the IVR and DC domains, whereas NRF2 mutations concentrate in the DLG and ETGE motifs (21) (22) . The high frequency of mutagenesis in these critical regions required for KEAP1-mediated degradation of NRF2 strongly supports the contention that high levels of NRF2 activity facilitates a selective advantage for tumor growth, can cause chemotherapeutic resistance, and correlates with a poor prognosis (18, 22) .
We previously identified two lung-derived KEAP1-DC mutations, one of which is a homozygous mutation at G364 (to cysteine; G364C), whereas the other is a heterozygous mutation at G430 (to cysteine; G430C) (17) . The heterozygous G430C mutation was a somatic mutation identified from a human patient, whereas the G364C mutation was identified from cancer-derived cell lines. To clarify how a heterozygous 
Materials and Methods

Plasmid construction.
Mutant mouse Keap1 cDNAs were generated by PCR-based mutagenesis using a site-directed mutagenesis kit (Stratagene CMV-based expression vectors of FLAG-tagged Keap1 WT and Keap1 mutant were generated as described (13) . Sequences of the primers used are available upon request.
Transfection and luciferase assays. The 293T cell line is a human renal epithelial cell line transformed with adenovirus EIA and SV40 large T antigen. The cell line was originally purchased from American Type Culture Collection. We have used frozen primary stocks of this cell line in this laboratory for years (13) . Since 293T cells were used only for the overexpression experiments, in this study we routinely monitored the cell morphology, but did not test or authenticate the cells line further. Transfection experiments were performed as described (9) by using Lipofectamine-plus (Invitrogen).
Luciferase assays were performed with the Dual-Luciferase reporter assay system (Promega). Keap1 and Nrf2 mutant expression plasmids were transfected into 293T cells in combination with a pNqo1-ARE reporter plasmid (24) and pRL-TK transfection control plasmid.
Generation of transgenic mice. Transgenic mice were generated as described (13 mutant mice examined in this study were from a mixed genetic background, with contributions from 129Sv/J, C57BL/6J and ICR strains. More than three independent animals from each line were examined to determine body weights.
Histology. For Hematoxylin and Eosin (HE) staining, stomachs and esophagi of P10 pups were fixed in 3.7% formalin and embedded into paraffin. For immunohistochemical staining, the stomachs of P10 pups were processed as previously described (10).
Real-time PCR analysis. Real-time PCR was performed using an ABI7300 system (Applied BioScience). Total RNA was extracted from mouse forestomachs using ISOGEN (Nippon Gene). One μg total RNA was utilized to synthesize cDNA using a Superscript II kit (Life Technologies). The mouse Nqo1 primers were described previously (25) .
Immunoprecipitation and immunoblot analyses.
To examine Keap1 dimerization, HA-tagged and FLAG-tagged Keap1 expression vectors were co-transfected into 293T cells. Whole cell extracts were prepared in a lysis buffer (13) and subjected to immunoprecipitation using an anti-Flag M2-Agarose Affinity Gel (A-2220, Sigma). After washing in the lysis buffer, immune-complexes were visualized by immunoblot analysis using anti-HA (3F10, Roche) and anti-Flag (A-8592, Sigma)
antibodies. Keap1 protein was detected by immunoblot analyses using a rat anti-mouse monoclonal Keap1 antibody (clone #144) (26) . Anti-αTubulin antibodies (Sigma) were utilized as a loading control. (16, 19, 22, 27) . A subset of these mutations cluster in the NRF2-KEAP1 interface and lead to constitutive NRF2 activation. We surmised that, since the Keap1 G430C mutant was identified as a somatic, heterozygous mutation in vivo, the Keap1 G430C mutant might function in a dominant-negative manner (16, 27 ). Indeed, when tested in luciferase reporter assays, the Keap1 G430C was able to impair Keap1 WT activity ( Supplementary Fig. S2 ). (Fig. 3D) . These results support our contention that the cancer-analogous Keap1 G430C mutant functions in a dominant negative manner in vivo.
Keap1 loss-of-dimerization mutants cannot inhibit Nrf2 activity in vivo.
Ubiquitination of Nrf2 requires Keap1 homodimerization, a process that requires the Keap1 BTB domain for Keap1-Keap1 interactions. (1, 11) . Thus, for a dominant 4D ). These results demonstrate that Keap1 homodimerization is a vital mechanism in vivo, which leads to a dominant-negative effect.
Keap1 loss-of-sensor-activity mutants cause dominant negative effects in vivo.
To further examine characteristics of the Keap1 mutants, we prepared Keap1 C273&288A , a loss-of-sensor-activity mutant (sensor-mutant), as C273 and C288 residues have been shown to be critical in maintaining repressor activity of Keap1 in vivo (29 
examined whether this mutant functions as a dominant negative molecule in vivo by using the double transgenic Keap1 complementation rescue approach. It has been suggested that cysteine-to-alanine substitution of these residues (C273&288A) leads to key tertiary changes that mimic the de-repression of Nrf2 caused by electrophiles (13, 30 S3A ). Immunoblotting analyses demonstrated that the Tg-Keap1 C273&288A expression was comparable to the Tg-Keap1 WT expression, and in double transgenic mice overall expression of Keap1 was increased ( Supplementary Fig. S3B ). 
Discussion
Recently several somatic KEAP1 mutations have been identified from genotypic screens of cancers and cancer-derived cell lines (reviewed by (20) ). Cancers that have shown increased propensity for Keap1 mutations include lung, gall bladder, head and neck, and breast cancers (17, 18, 22, 31, 32) . Intriguingly, it has become clearer that selective pressures in the microenvironment of some cancers enables mutations to occur that allow for constitutive activation of NRF2.
Subsequent heightened expression of antioxidant-and drug metabolism-related enzymes and drug resistant transporters provides a major advantage for cancer cells in evading the effects of chemotherapeutic drugs. NRF2-mediated activation of these enzymes allows for increased levels of glutathione, increased detoxification, and increased efflux transport (3, 33, 34) . Along similar lines, constitutive activation of NRF2 aids in cellular proliferation, although these mechanisms are currently poorly understood.
Translational research has also demonstrated that these mechanisms are critical to progression-free survival, with a poor prognosis of patients that have mutations in regions essential for functional KEAP1 activity (22, 31, 35) . NRF2 mutations in the DLG and ETGE motifs also significantly interfere with KEAP1-mediated degradation of NRF2 in cancers (22) . Thus, the identification of a significant number of KEAP1 and NRF2 mutations and epidemiological links of KEAP1 mutations to a poor prognosis highlight the importance of KEAP1 in preventing the cancer progression.
In this study, we have demonstrated that mutated forms of KEAP1 analogous to documented cancer genotypes, Keap1 G430C and Keap1 luciferase reporter assays have identified that G430C and G364C mutations lead to loss of Keap1 function and constitutive Nrf2 activation (17) . However, it is difficult to extrapolate the in vitro system results to a heterozygous cancer environment, as luciferase assays rely on a complex mixture of reagents. Furthermore, the results do not necessarily translate to the in vivo situation. Thus, as summarized in Figure 6 , we utilized the double transgenic complementation model system in which both Tg-Keap1
WT and Tg-Keap1 mutant are co-expressed to approximately similar levels. We attempted to better represent the type of heterozygous mutation likely to be found in the human condition in which homozygous mutations are less prevalent (20) . Our present analysis enabled an in vivo assessment under physiological conditions in terms of expression levels and cellular environment. This result strongly supports the idea that a "single-hit" heterozygous KEAP1 mutation is sufficient to generate a selective advantage in the cancer microenvironment.
The stoichiometry of Keap1 is another critical aspect in understanding mechanistically how the dominant negative effect can occur. As Keap1 heterozygous mice exhibit a benign phenotype (36) , it was difficult to comprehend how a single KEAP1 mutation in a human cancer could lead to efficacious increases in chemo-resistance. A key finding was the discovery that the ETGE and DLG motifs in the Nrf2-Neh2 region bind to Keap1 at two-sites (37, 38) , with a binding stoichiometry between Keap1 and Nrf2 of 2:1 (Fig. 6A ). This two-sites substrate-binding model led to the hypothesis that a Keap1 mutant protein could sequester Keap1 WT into an inactive heterodimer (Fig. 6B ), leading to a functional loss of Keap1 WT that could 50%.
To demonstrate that a dominant negative heterodimer was mechanistically possible, deletion of the entire BTB domain (ΔBTB) and a point mutation in a critical amino acid sequence (mutHKVVL) were conducted, and the resultant transgenes were placed in WT activity in vivo. C273 and C288 are critical reactive residues that respond to electrophiles, and sulfhydryl modification of these amino acids can cause changes in the tertiary structure of Keap1 that lead to loss of Nrf2 degradation (Fig. 6D) , allowing Nrf2 levels to increase and drive transcription of Nrf2-mediated target genes (37, 38 In conclusion, our results using the double transgenic complementation mouse models provide evidence for the presence of a dominant negative effect in vivo that is analogous to heterozygous mutations that have been identified in human patients.
Furthermore, heterozygous mutations in critical signaling cysteines (i.e. Keap1 form a heterodimer. HA-tagged and FLAG-tagged molecules were co-transfected into 293T cells. Whole cell extracts were prepared and subjected to immunoprecipitation with anti-FLAG beads (IP) and immunoblotted with anti-HA and anti-FLAG antibodies.
An association between HA-tagged and FLAG-tagged molecules can be seen for 
